| Scotland |
cohort |
3 |
— |
|
| screened controls |
cohort |
3 |
1 |
6,068 screened controls with no lifetime subclinical motor or vocal tics, controls |
| SCZ |
phenotype |
12 |
9 |
SCZ, Schizophrenia, schizophrenia |
| SD |
phenotype |
2 |
2 |
self-directedness, substance dependence |
| Sdc3 |
gene |
2 |
1 |
syndecan 3 |
| SDPS probands |
cohort |
2 |
2 |
White male probands, probands |
| SDS |
drug |
8 |
1 |
sodium dodecyl sulfate |
| SEC16B |
gene |
2 |
2 |
|
| secondary antibody |
drug |
4 |
2 |
|
| secondary phenotype |
phenotype |
2 |
2 |
|
| secondary sex characteristics |
phenotype |
2 |
2 |
|
| secondary signal |
variant |
2 |
1 |
|
| second-hand smoke |
drug |
5 |
1 |
SHS, environmental tobacco smoke, passive exposure to smoking, passive smoking, second-hand smoke, secondhand smoke |
| sedative dependence |
phenotype |
8 |
7 |
Sedatives dependence, sedative, sedative use disorder, sedative use disorders, use/dependence on sedatives |
| sedative effects |
phenotype |
12 |
8 |
alcohol’s sedative effects, sedation, sedative, sedative effects, sedative effects of alcohol |
| sedatives |
drug |
42 |
20 |
Alcohol-induced sedation, alcohol sedation, alcohol-induced sedation, marked sedation, non-prescription sedatives |
| segmental duplications |
variant |
2 |
1 |
|
| Seizure susceptibility |
phenotype |
2 |
1 |
increased seizure susceptibility |
| selected lines |
cohort |
2 |
1 |
|
| selection bias |
phenotype |
2 |
2 |
|
